ACCURAY INC

Hey there! Let's break down some important news about Accuray Inc. in a way that makes sense, without all the fancy finance talk. Think of this as me explaining it to you over coffee.

---

1. What happened?

Okay, so here's the big news about Accuray: The company recently found errors in its past financial reports. Specifically, these errors related to a footnote on "remaining performance obligations" (RPO), which represents future revenue the company expects from signed contracts.

Because of these errors, Accuray's Audit Committee (the group overseeing the company's financial reporting) and its independent auditors have concluded that investors should no longer rely on the financial statements for the fiscal year ended June 30, 2025, and the quarter ended September 30, 2025.

Here's the crucial part: Accuray emphasizes that these errors do not change the main financial numbers like sales, profits, or cash flow. The issue is an error in a specific disclosure, not in the company's overall financial health. The RPO overstatement for the fiscal year ended June 30, 2025, was approximately $20 million.

2. When did it happen?

Accuray made this announcement on February 8, 2026. The financial reports now considered unreliable cover the fiscal year ended June 30, 2025, and the quarter ended September 30, 2025.

3. Why did it happen?

It wasn't out of the blue; here's a little background on what led up to it: Accuray re-evaluated how it classified certain sales orders for its systems and upgrades as "remaining performance obligations" (RPO). (Remember, RPO is money the company expects to earn in the future from contracts it has already signed.)

The company realized its old method was incorrect. Under a specific accounting rule (ASC 606), Accuray had included some sales orders that shouldn't have been counted as RPO. This was because the customer deposits weren't significant enough to act as "termination penalties" if the contract fell through. Essentially, Accuray was overstating the future revenue it had locked in through these specific obligations, by approximately $20 million for fiscal year 2025.

This discovery also revealed that Accuray's internal systems and processes for financial reporting (what accountants call "internal control over financial reporting" and "disclosure controls and procedures") were not effective as of June 30, 2025. The company found "material weaknesses," meaning significant gaps existed in how it reviewed and analyzed information for its financial disclosures. Specifically, these weaknesses included inadequate review procedures for complex accounting judgments and insufficient personnel with appropriate accounting expertise to ensure accurate RPO classification.

4. Why does this matter?

So, why should we care about this? This is a big deal for a few reasons:

• The Good News: Accuray has stated that these errors do not impact its core financial results like sales, profits, or cash flow. This means the actual business performance numbers remain accurate. The problem is isolated to a specific footnote disclosure about future revenue expectations, which was overstated by approximately $20 million for FY25.
• The Not-So-Good News: Even if the main numbers are fine, declaring past financial statements "unreliable" is serious. It means investors cannot fully trust the detailed disclosures in those reports. More importantly, finding "material weaknesses" in internal controls is a big red flag. It suggests that Accuray's processes for ensuring accurate financial reporting were not robust enough, which can shake investor confidence. This highlights a need for stronger financial oversight and expertise within the company.

5. Who is affected?

This news isn't just about the company; it impacts several groups:

• Accuray's Employees: The finance and accounting teams will face significant pressure to fix these issues and strengthen controls, leading to more work and scrutiny.
• Customers (Hospitals/Clinics): This accounting issue does not directly affect them. Their orders and services should continue as normal.
• Competitors: They might view this as a slight stumble for Accuray, but it's unlikely to have a direct impact on their own business.
• Investors/Shareholders: This group faces the biggest impact. While core financials remain unchanged, news of "unreliable statements" and "material weaknesses" can erode confidence. This could potentially cause the stock price to drop, at least temporarily, as investors process the news and await corrected reports and remediation plans.
• Patients: This financial reporting issue does not affect patients.

6. What happens next?

What's the game plan now? So, what can we expect to see unfold from here?

Immediately, Accuray will work to correct these errors. The company plans to file amended reports (Form 10-K/A for the fiscal year ended June 30, 2025, and Form 10-Q/A for the quarter ended September 30, 2025). Accuray expects to file these amended reports within 45 days of the February 8, 2026 announcement. These amended reports will not only fix the RPO disclosure but also detail the company's revised conclusions about its internal controls and its concrete plan to fix the identified "material weaknesses."

Accuray is working closely with its independent auditors, Grant Thornton LLP. The company also announced it will file its next regular quarterly report, Form 10-Q for the quarter ended December 31, 2025 (Q2 FY26), within a five-day extension period. This means the filing, originally due on February 14, 2026, is now expected by February 19, 2026. Long-term, Accuray must successfully implement its remediation plan to strengthen internal controls and restore investor confidence in its financial reporting processes. Management has committed to dedicating significant resources to promptly address these control deficiencies.

7. What should investors/traders know?

Alright, for us traders and folks watching the stock, what's the bottom line? Here's what you should keep in mind if you're considering Accuray stock:

• Key Dates to Watch: Look for the filing of the amended reports (10-K/A and 10-Q/A) by their expected deadline of late March 2026, and the Q2 FY26 10-Q by February 19, 2026. Pay close attention to the details of Accuray's plan to fix the "material weaknesses" in its internal controls, especially how it intends to improve review procedures and staffing. Any further delays or new issues would be a significant concern.
• Potential Stock Price Impact: While Accuray stressed that core financials (sales, profit) remain unaffected, news of "unreliable statements" and "material weaknesses" often triggers a negative reaction in the stock market. Investors tend to be wary of companies with control issues. The stock price might dip, but the fact that the core business performance is not being restated could limit the severity of the drop.
• The Bigger Picture: This is an accounting and control issue, not a problem with Accuray's products or sales performance. However, strong financial controls are fundamental for any publicly traded company. It's a reminder that even seemingly small accounting details, like an RPO overstatement of $20 million, can significantly impact investor perception and trust. Successful remediation is crucial for rebuilding that trust.